Ardsley Advisory Partners bought a new position in Mylan N.V. (NASDAQ:MYL) in the second quarter, according to its most recent disclosure with the SEC. The firm bought 7,500 shares of the company’s stock, valued at approximately $291,000.
Other institutional investors and hedge funds also recently modified their holdings of the company. Waldron LP acquired a new stake in shares of Mylan N.V. during the 1st quarter worth about $229,000. Sei Investments Co. increased its position in shares of Mylan N.V. by 1.0% during the 1st quarter. Sei Investments Co. now owns 13,870 shares of the company’s stock worth $541,000 after purchasing an additional 134 shares during the last quarter. Teachers Advisors LLC increased its position in shares of Mylan N.V. by 128.5% during the 1st quarter. Teachers Advisors LLC now owns 1,943,541 shares of the company’s stock worth $75,779,000 after purchasing an additional 1,093,160 shares during the last quarter. Ngam Advisors L.P. acquired a new stake in shares of Mylan N.V. during the 1st quarter worth about $1,543,000. Finally, Cleararc Capital Inc. increased its position in shares of Mylan N.V. by 0.6% during the 1st quarter. Cleararc Capital Inc. now owns 10,394 shares of the company’s stock worth $405,000 after purchasing an additional 67 shares during the last quarter. 71.98% of the stock is owned by institutional investors and hedge funds.
TRADEMARK VIOLATION WARNING: This report was posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this report on another domain, it was illegally stolen and reposted in violation of United States and international copyright & trademark law. The legal version of this report can be viewed at https://www.dispatchtribunal.com/2017/10/27/ardsley-advisory-partners-takes-position-in-mylan-n-v-myl.html.
Mylan N.V. (NASDAQ MYL) traded down 0.16% on Friday, reaching $38.51. The company’s stock had a trading volume of 1,081,340 shares. Mylan N.V. has a 52 week low of $29.39 and a 52 week high of $45.87. The firm’s 50 day moving average price is $34.77 and its 200-day moving average price is $36.25. The company has a market capitalization of $20.65 billion, a price-to-earnings ratio of 31.13 and a beta of 1.30.
Mylan N.V. (NASDAQ:MYL) last announced its quarterly earnings results on Wednesday, August 9th. The company reported $1.10 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $1.18 by ($0.08). The firm had revenue of $2.96 billion for the quarter, compared to analyst estimates of $3 billion. Mylan N.V. had a return on equity of 22.42% and a net margin of 5.51%. The business’s revenue was up 15.7% compared to the same quarter last year. During the same quarter in the prior year, the company earned $1.16 earnings per share. On average, equities analysts predict that Mylan N.V. will post $4.58 EPS for the current year.
Several equities analysts have weighed in on MYL shares. Cowen and Company reaffirmed a “market perform” rating and issued a $36.00 target price (up from $30.00) on shares of Mylan N.V. in a research report on Thursday, October 5th. Zacks Investment Research raised Mylan N.V. from a “strong sell” rating to a “hold” rating and set a $43.00 target price for the company in a research report on Tuesday, October 10th. Royal Bank Of Canada set a $41.00 target price on Mylan N.V. and gave the company a “hold” rating in a research report on Sunday, July 16th. Citigroup Inc. set a $42.00 target price on Mylan N.V. and gave the company a “buy” rating in a research report on Wednesday, October 4th. Finally, BidaskClub upgraded Mylan N.V. from a “strong sell” rating to a “sell” rating in a research note on Thursday, September 7th. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating and thirteen have given a buy rating to the company’s stock. Mylan N.V. currently has a consensus rating of “Buy” and an average price target of $41.21.
Mylan N.V. Company Profile
Mylan N.V. is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic and branded generic products for resale by others; specialty pharmaceuticals, and active pharmaceutical ingredients (APIs). It operates through two segments: Generics and Specialty.
Receive News & Ratings for Mylan N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan N.V. and related companies with MarketBeat.com's FREE daily email newsletter.